Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18970429 | 0.79 | HTR2A (0.39) | SMN1; SMN2KMT2AMEN1ALDH1A1GLA | |
| SCHEMBL31052656 | 0.75 | PDE4D (0.41) | SMN1; SMN2KMT2AMEN1ALDH1A1GLA | |
| SCHEMBL203402 | 0.72 | ALDH1A1 (0.58) | SMN1; SMN2KMT2AMEN1ALDH1A1GLA | |
| SCHEMBL18186534 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMEN1ALDH1A1GLA | |
| SCHEMBL7939404 | 0.72 | HTR2A (0.47) | SMN1; SMN2KMT2AMEN1ALDH1A1GLA | |
| SCHEMBL10439849 | 0.71 | CLCN2 (0.55) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL202047 | 0.71 | KDM4E (0.46) | SMN1; SMN2KMT2AMEN1ALDH1A1GLA | |
| SCHEMBL23723768 | 0.71 | ALDH1A1 (0.41) | SMN1; SMN2KMT2AMEN1ALDH1A1GLA | |
| SCHEMBL20855913 | 0.70 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2AMEN1ALDH1A1GLA | |
| SCHEMBL19756643 | 0.70 | HTR2A (0.46) | SMN1; SMN2KMT2AMEN1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755944-B1 | BIARYLDERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2017-06-14 | — | — | EP | disclosed |
| EP-2755944-B1 | BIARYLDERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2017-06-14 | — | — | EP | disclosed |
| US-9624159-B2 | Aniline derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2017-04-18 | — | — | US | disclosed |
| US-9624159-B2 | Aniline derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2017-04-18 | — | — | US | disclosed |
| US-20160199330-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2016-07-14 | — | — | US | disclosed |
| US-20160199330-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2016-07-14 | — | — | US | disclosed |
| US-9249085-B2 | Aniline derivatives, their preparation and their therapeutic application | FOVEA PHARMACEUTICALS (FR) | 2016-02-02 | — | — | US | disclosed |
| US-9249085-B2 | Aniline derivatives, their preparation and their therapeutic application | FOVEA PHARMACEUTICALS (FR) | 2016-02-02 | — | — | US | disclosed |
| US-20140350019-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2014-11-27 | — | — | US | disclosed |
| US-20140350019-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2014-11-27 | — | — | US | disclosed |
| EP-2755944-A2 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Fovea Pharmaceuticals (FR) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013037705-A9 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013037705-A9 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013037705-A2 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037705-A2 | ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350019-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CYP11B1, CYP11B2, ARG2 | SMN1; SMN2 3830/4885KMT2A 3082/4885MEN1 1723/4885 |
| US-20160199330-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CYP11B1, ARG2, CYP11B2 | SMN1; SMN2 3891/4885KMT2A 3363/4885MEN1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.